Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in active idiopathic inflammatory myopathies
2023-505314-20-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Myopathies comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jan 2023; status: completed.
02
Drugs
nipocalimab
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on 2023-505314-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505314-20-00.